Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Bullboard (CSE:RVV)

View:
Post by TheWeakendzon Dec 09, 2024 7:33pm

Keep an eye on XBOT

Realbotix.  Do your own DD
Post by ElBortoon Nov 23, 2024 4:43pm

Psilocybin in the Treatment of Neurological Brain Injury

https://stockhouse.com/news/press-releases/2024/11/12/revive-therapeutics-announces-publication-demonstrating-novel-therapeutic
Post by RBLCommon Oct 31, 2024 8:21am

NEWS: Revive Therapeutics Provides Update on Research...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure READ MORE  
Comment by hk1966on Jun 26, 2024 10:13pm

RE: June 10, 2024 (GLOBE NEWSWIRE)

AKA go pound salt you'll never get approved 
Post by G1945Von Jun 11, 2024 5:15am

June 10, 2024 (GLOBE NEWSWIRE)

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product "The FDA has determined that the Product should follow the De Novo regulatory pathway, and the Company ...more  
Post by adoubleyouon May 03, 2024 6:52pm

Next week's live was canceled per ftmig Twitter

Rvv posted on their handle for X that they will schedule something soon on a different platform.  
Post by cool888on May 02, 2024 7:57pm

Rescheduled - Wednesday May 8th at 2pm ET.

https://twitter.com/FTMInvest/status/1786167849834127412  
Post by adoubleyouon May 02, 2024 7:55pm

Mike frank to go live Wednesday may 8th at 7pm et

Apologies for our failed x space earlier with Revive_RVV  RVV CEO Michael Frank. For all that were tuned in we hope you weren't too inconvenienced and we hope to make it up to those ...more  
Comment by G1945Von May 02, 2024 3:38pm

RE:An Overview & Q&A with CEO Michael Frank May 2nd 4pm

Is the 4 PM EDT Q&A strictly for X subscribers? G1945V
Post by Tesla888on Apr 29, 2024 2:45pm

An Overview & Q&A with CEO Michael Frank May 2nd 4pm

Link - https://twitter.com/ftminvest/status/1784693118308122941?s=46&t=LsRlg0oC9EbPON1oBKpUbw
Post by Tesla888on Apr 18, 2024 8:19am

$RVV - FDA mtg June 7th

https://ca.finance.yahoo.com/news/revive-therapeutics-announces-fda-acceptance-110000050.html
Post by Tesla888on Apr 02, 2024 8:36am

$RVV News

https://ca.finance.yahoo.com/news/revive-therapeutics-provides-psilocybin-clinical-113000679.html
Post by Tesla888on Mar 19, 2024 9:01pm

$RVV - we get hour money back ? Hope so !!

https://ca.finance.yahoo.com/news/revive-therapeutics-submit-type-c-110000338.html  
Post by Betteryear2on Mar 12, 2024 8:48am

Revive Therapeutics Provides Corporate Update

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities